Valuation: Fifty 1 Labs, Inc.

Market Cap 281K 252K 232K 210K 393K 26.73M 400K 2.77M 1.11M 14.06M 1.06M 1.03M 44.34M P/E 2009
-0.05x
P/E 2010 -0.01x
Enterprise Value 12.55M 11.24M 10.34M 9.37M 17.52M 1.19B 17.84M 123M 49.51M 627M 47.12M 46.11M 1.98B EV / Sales 2009
1.86x
EV / Sales 2010 2.41x
Free-Float
47.75%
Yield 2009 *
-
Yield 2010 -
1 day-50.00%
Current month-60.00%
1 month-60.00%
3 months-80.00%
6 months-75.00%
Current year-80.00%
1 week 0
Extreme 0.0001
0
1 month 0
Extreme 0.0001
0
Current year 0
Extreme 0.0001
0
1 year 0
Extreme 0.0001
0
3 years 0
Extreme 0.0001
0.05
5 years 0
Extreme 0.0001
0.2
10 years 0
Extreme 0.0001
0.23
Manager TitleAgeSince
Chief Executive Officer 47 -
President - -
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 49 29/04/2025
Chairman - 11/07/2023
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-50.00%0.00%-94.44%-99.00% 118K
-0.62%-1.87%+46.31%+56.99% 63.77B
+0.35%+3.20%+14.92%+84.55% 56.37B
+0.53%+1.96%+15.37%+106.81% 54.62B
-2.81%-4.31%+23.50%+50.90% 44.06B
-0.33%-1.93%+20.15%+98.45% 42.11B
+0.55%+2.31%+224.97%+942.56% 41B
+3.27%+47.96%+112.67%+96.48% 34.92B
+1.22%-1.44%+14.89%+47.15% 32.82B
+0.89%+20.55%-42.03%+373.03% 24.7B
Average -4.69%+6.79%+33.63%+175.79% 39.43B
Weighted average by Cap. +0.18%+5.44%+48.50%+186.13%

Financials

2009 2010
Net sales 5.41M 4.85M 4.46M 4.04M 7.55M 514M 7.69M 53.16M 21.34M 270M 20.31M 19.88M 852M 5.11M 4.57M 4.21M 3.81M 7.13M 485M 7.26M 50.17M 20.14M 255M 19.16M 18.76M 804M
Net income -2.23M -2M -1.84M -1.67M -3.11M -212M -3.17M -21.92M -8.8M -111M -8.37M -8.2M -351M -1.89M -1.7M -1.56M -1.41M -2.64M -180M -2.69M -18.61M -7.47M -94.61M -7.11M -6.96M -298M
Net Debt 9.96M 8.92M 8.2M 7.43M 13.89M 945M 14.15M 97.81M 39.26M 497M 37.36M 36.57M 1.57B 12.27M 10.99M 10.11M 9.16M 17.12M 1.17B 17.44M 121M 48.4M 613M 46.06M 45.08M 1.93B
Logo Fifty 1 Labs, Inc.
Fifty 1 Labs, Inc. is a biotechnology and life sciences company. The Company focuses on peptide products, peptide discovery, AI-enabled research, and clinical development. It also focuses on peptide science, musculoskeletal health, sports performance, injury recovery, rehabilitation, and evidence-driven wellness. It owns 51, LLC, its sports nutrition subsidiary offering a premium line of supplements including pre-workout formulas, BCAAs, ION+ Electrolyte Formula, Turmeric Gummies, and Ashwagandha Gummies designed to enhance athletic performance, recovery, and overall health. It has acquired a musculoskeletal recovery product line. The product line includes five key product concepts designed to support the Company's peptide and musculoskeletal health markets. The portfolio includes natural health products focused on connective tissue recovery, inflammation support, post-surgical recovery nutrition, joint and cartilage support, and an investigational BPC-157-focused research platform.
Employees
2
Date Price Change Volume
30/10/26 US$0.000100 -50.00% 315,000
29/10/26 US$0.000200 0.00% 15,000
28/10/26 US$0.000200 0.00% 804,000
27/10/26 US$0.000200 0.00% 849,788
26/10/26 US$0.000200 +100.00% 1,392,400
  1. Stock Market
  2. Stocks
  3. FITY Stock